Tarsus bets $450M on Alkeus’ Stargardt drug
Tarsus bets $450M on Alkeus’ Stargardt drug
Tarsus Pharmaceuticals
Late clinical-stage biopharma developing therapeutic solutions for chronic diseases in eye care and beyond; lead product XDEMVY (lotilaner ophthalmic solution 0.25%) is the first and only FDA-approved treatment for Demodex blepharitis. In August 2026 it agreed to acquire Alkeus Pharmaceuticals and its Phase 3 Stargardt disease drug for $450 million.
Company Info
Sector:Ophthalmology / Biopharmaceuticals
Headquarters:Irvine, California, USA
Founded:2016
Website:tarsusrx.com/
Upcoming Milestones & Key Dates
2026-08
M&A
Alkeus Pharmaceuticals acquisition announced ($450M)
2026-08
Pipeline
Acquired Stargardt disease program integration
Clinical Development Pipeline
XDEMVY (lotilaner 0.25%)
Target: Parasitic (Demodex mites)TP-04
Target: Investigational gelTP-05
Target: Oral systemic antiparasiticRecent News
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
Leadership Team
Bobak 'Bobby' Azamian
Chairman, President and CEO (co-founder)
Michael Ackermann
Co-founder